Search

Your search keyword '"Moroni, M."' showing total 68 results

Search Constraints

Start Over You searched for: Author "Moroni, M." Remove constraint Author: "Moroni, M." Topic anti-hiv agents Remove constraint Topic: anti-hiv agents
68 results on '"Moroni, M."'

Search Results

1. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011.

2. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.

3. Key questions in antiretroviral therapy: Italian Consensus Workshop (2005).

4. [13C]Methionine breath test: a novel method to detect antiretroviral drug-related mitochondrial toxicity.

5. IL-7/IL-7 receptor system regulation following IL-2 immunotherapy in HIV-infected patients.

7. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.

8. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors.

9. Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals.

10. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.

11. Epidemiological spread of drug-resistant HIV-1 strains.

12. Sexual behaviour of heterosexual individuals with HIV infection naive for antiretroviral therapy in Italy.

13. Predictive role of the three-month CD4 cell count in the long-term clinical outcome of the first HAART regimen.

15. A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection.

16. Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group.

17. Decreasing incidence of CNS AIDS-defining events associated with antiretroviral therapy.

18. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.

19. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.

20. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.

21. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.

22. HIV treatment: an overview.

23. CD4 cell counts at the third month of HAART may predict clinical failure.

24. Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine.

25. CD4+CD7-lymphocyte subset is expanded in HIV-infected patients with low CD4 cell count rescue during highly active antiretroviral therapy.

26. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy.

27. Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial.

29. Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.

30. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.

31. Indinavir-related alopecia.

32. Overview on HIV-1-related drug resistance: from theory to clinical practice.

33. Sharp drop in the prevalence of human cytomegalovirus leuko-DNAemia in HIV-infected patients following highly active antiretroviral therapy.

34. Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons.

35. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.

36. Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group.

37. A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.

38. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.

39. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.

40. Evolving treatment implementation among HIV- infected pregnant women and their partners: Results from a national surveillance study in Italy, 2001-2015

41. Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy

42. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study

43. Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice

44. Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort

45. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART

46. Pregnancy Outcomes Among ART-Naive and ART-Experienced HIV-Positive Women: Data From the ICONA Foundation Study Group, Years 1997-2013

47. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

48. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

49. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011

50. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

Catalog

Books, media, physical & digital resources